Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Innoviva, Inc. announced its management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 10:00 a.m. E.T. The conference will be held virtually, and a live webcast will be available on the Investor Relations section of the Company’s website. Innoviva is a diversified holding company with a royalties portfolio, a critical care and infectious disease platform (Innoviva Specialty Therapeutics), and strategic investments in healthcare assets.
Investors can stream Innoviva fireside chat at Oppenheimer health conference
Innoviva, Inc. (NASDAQ: INVA) will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 10:00 a.m. E.T. The conference will be held virtually, and a live webcast will be available on the company's investor relations website, with an archived replay accessible afterward. Innoviva is a diversified holding company with a royalties portfolio, a critical care and infectious disease platform (Innoviva Specialty Therapeutics), and strategic healthcare investments.
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Innoviva, Inc. will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 10:00 a.m. E.T. The virtual event's webcast will be accessible through the Investor Relations section of the company's website. Innoviva is a diversified holding company with a royalties portfolio, the Innoviva Specialty Therapeutics platform, and healthcare investments, including respiratory assets with GSK and various infectious disease and critical care assets.
Innoviva stock gains BTIG coverage with buy rating on royalty windfall
BTIG initiated coverage on Innoviva Inc. (NASDAQ:INVA) with a Buy rating and a $35.00 price target, expecting the company to benefit from over $1.2 billion in royalty rights by 2030 for two COPD and asthma therapies. Innoviva is considered undervalued, holding more cash than debt, and has a strong financial position, with plans to redeploy capital into infectious disease therapies, strategic investments, and shareholder returns. The company's recent acquisition of an extended-release platform and potential accretive acquisitions, alongside expected net income growth, present significant upside potential for 2026.
BTIG Initiates Coverage of Innoviva (INVA) with Buy Recommendation
BTIG has initiated coverage of Innoviva (INVA) with a Buy recommendation, according to a Fintel report from February 17, 2026. Analysts project a 46.04% upside to an average one-year price target of $33.15/share. Fund sentiment indicates a slight decrease in the number of institutional owners, though the put/call ratio suggests a bullish outlook.
BTIG Initiates Coverage on Innoviva (INVA) with a 'Buy' Rating | INVA Stock News
BTIG has initiated coverage on Innoviva (INVA) with a 'Buy' rating and a price target of $35.00, according to analyst Julian Harrison. This new rating adds to the mixed sentiment for INVA, which has seen varying ratings and price targets from other firms like HC Wainwright & Co., Cantor Fitzgerald, Goldman Sachs, and Oppenheimer. Innoviva is a healthcare company with a portfolio of royalties and operating assets, and while analysts forecast an average upside of 43.17%, GuruFocus estimates a 13% downside based on its GF Value.
Innoviva, Inc. (INVA) Stock Analysis: Potential 43% Upside Captivates Investors
Innoviva, Inc. (INVA) is gaining investor attention due to its strong growth potential, strategic focus on pharmaceutical products like respiratory medications, and promising development pipeline including Zoliflodacin. The company boasts remarkable revenue growth, robust EPS, and an impressive free cash flow, with analysts projecting a 43.17% potential upside. Innoviva's strategic reinvestment of profits and collaborations further strengthen its competitive edge in the biotechnology industry.
(INVA) Movement as an Input in Quant Signal Sets
This article analyzes Innoviva Inc. (NASDAQ: INVA) using AI-generated quant signals, highlighting prevailing positive sentiment but noting elevated downside risk due to a lack of long-term support. It presents specific institutional trading strategies for long, momentum breakout, and short positions, along with multi-timeframe signal analysis for near, mid, and long-term horizons.
Innoviva stock hits 52-week high at $22.81 By Investing.com
Innoviva Inc.'s stock recently hit a 52-week high of $22.81, reflecting significant growth and positive market sentiment. The company exhibits strong financial health with a P/E ratio of 14.8 and a PEG ratio of 0.24, suggesting it may be undervalued. This performance, coupled with a low beta, underscores investor confidence and effective strategic initiatives.
Innoviva stock hits 52-week high at $22.81 By Investing.com
Innoviva Inc.'s stock reached a new 52-week high of $22.81, marking significant growth over the past year with a 25.03% increase. The company exhibits strong financial health with a healthy P/E ratio of 14.8 and a PEG ratio of 0.24, suggesting potential undervaluation relative to its growth prospects. This performance, coupled with a low beta, indicates investor confidence and strategic effectiveness.
Innoviva's Financial Metrics Show Resilience Amid Long-Term Growth Challenges
Innoviva, Inc. has seen a positive score adjustment due to strong financial metrics, including a high Return on Capital Employed (30.79%), robust operating cash flow (USD 200.62 million), and a low Debt to EBITDA ratio (0.93 times). Despite a negative long-term operating profit growth rate over the past five years, the company has demonstrated resilience with a 9.67% stock return and 73.3% profit increase in the last year. This evaluation adjustment highlights Innoviva's evolving financial health and market position.
Innoviva stock hits 52-week high at $22.81
Innoviva Inc. (INVA) has reached a new 52-week high of $22.81, trading just under its peak at $22.74, showing a 25.03% increase over the past year. The company’s financial health is rated "GREAT" with a low beta of 0.45, suggesting lower volatility, and favorable P/E and PEG ratios. Additionally, Inova Technology, which appears to be a separate entity, recently received FDA approval for NUZOLVENCE, a new gonorrhea treatment, leading to an increased price target from H.C. Wainwright.
New York State Common Retirement Fund Decreases Stock Holdings in Innoviva, Inc. $INVA
The New York State Common Retirement Fund significantly reduced its stake in Innoviva, Inc. (NASDAQ:INVA) by 74.7% in Q3, selling 84,700 shares and retaining 28,692 shares valued at $524,000. Despite this reduction, several other institutional investors substantially increased their positions, contributing to 99.12% institutional ownership. Analysts maintain a "Moderate Buy" rating for Innoviva with an average price target of $38.80, while the stock trades around $21.84.
Allianz Asset Management GmbH Has $3.59 Million Holdings in Innoviva, Inc. $INVA
Allianz Asset Management GmbH significantly increased its stake in Innoviva, Inc. (NASDAQ:INVA) by 139.2% in the third quarter, now holding 196,831 shares valued at $3.59 million. Institutional investors collectively own 99.12% of the company, which trades at $21.84 with a market cap of $1.63 billion. Analysts have a "Moderate Buy" consensus rating with a target price of $38.80, and several firms have recently raised their price objectives.
Innoviva Inc (NASDAQ:INVA) Presents a Compelling Value Investment Case
This article identifies Innoviva Inc (NASDAQ:INVA) as a compelling value investment due to its low valuation compared to its industry and the wider market. The company demonstrates strong financial health with high profitability and robust earnings power, suggesting it is not a "value trap." Furthermore, Innoviva shows accelerating growth projections for both EPS and revenue, indicating potential for market reassessment and future appreciation.
Innoviva, Inc.'s (NASDAQ:INVA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Innoviva's stock has shown strong momentum, with a 16% increase in the past three months. While the company boasts a decent 13% Return on Equity (ROE) and high profit retention, its net income has shrunk by 27% over the last five years, contrasting with industry growth of 8.6%. Analysts, however, are forecasting a significant improvement in the company's earnings growth rate.
Liquidity Mapping Around (INVA) Price Events
This article provides a liquidity mapping analysis for Innoviva Inc. (NASDAQ: INVA), highlighting a near-term strong sentiment with a neutral mid and long-term outlook. It details an exceptional 31.3:1 risk-reward setup targeting a 9.3% gain, and outlines specific institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report also offers access to real-time AI-generated signals for INVA.
Innoviva, Inc. (NASDAQ:INVA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Innoviva, Inc. (NASDAQ:INVA) has received a consensus "Moderate Buy" rating from seven brokerages, with an average 12-month price target of $38.80. The company recently surpassed earnings expectations, reporting an EPS of $1.08 against an estimated $0.46 and revenue of $107.8 million versus $91.31 million. Institutional ownership of Innoviva is significant, with major funds increasing their stakes, underscoring confidence in the royalty-focused life sciences company.
Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Position in Innoviva, Inc. $INVA
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Innoviva, Inc. by 838.8% during the third quarter, now owning 0.18% of the company worth $2.11 million. Innoviva reported strong Q3 earnings, exceeding analyst expectations, with a healthy net margin and return on equity. Wall Street analysts maintain a "Moderate Buy" consensus rating for Innoviva, with an average price target considerably higher than its current trading price.
Innoviva (NASDAQ:INVA) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened
Innoviva (NASDAQ:INVA) shares recently passed above their 200-day moving average, trading as high as $19.83 before settling at $19.55. This technical positive aligns with a "Moderate Buy" consensus from analysts, who anticipate a price target of $38.80. The company also reported strong quarterly earnings, exceeding expectations with $1.08 EPS and $107.8 million in revenue.
Hussman Strategic Advisors Inc. Sells 168,000 Shares of Innoviva, Inc. $INVA
Hussman Strategic Advisors Inc. significantly reduced its stake in Innoviva, Inc. (NASDAQ:INVA) by 80% during the third quarter, selling 168,000 shares and retaining 42,000 shares. Despite this sale, Innoviva maintains high institutional ownership at 99.12%, with several other institutional investors modestly increasing their holdings. Analysts have a "Moderate Buy" consensus rating for Innoviva with an average price target of $38.80.
Innoviva, Inc. (INVA): Investor Outlook Highlights 66.5% Potential Upside
Innoviva, Inc. (INVA) shows a promising investor outlook with a potential upside of 66.5%, driven by an average analyst target price of $32.50. The biotechnology company, specializing in pharmaceutical products, exhibits strong financial health with a forward P/E of 9.59, 20.4% revenue growth, and over $132 million in free cash flow. Despite no dividend payout, its strategic partnerships and late-stage product pipeline, including Zoliflodacin, suggest significant future value and a potential buying opportunity given its oversold RSI.
Why (INVA) Price Action Is Critical for Tactical Trading
The article analyzes Innoviva Inc. (NASDAQ: INVA), highlighting a neutral sentiment across all time horizons and an oscillation pattern in play. It identifies a strong risk-reward short setup with significant downside potential against low risk. Several institutional trading strategies are provided, including position, momentum breakout, and risk hedging, along with detailed multi-timeframe signal analysis.
The Truth About Innoviva Inc: Why Everyone Is Suddenly Watching This ‘Boring’ Stock
Innoviva Inc (INVA) is gaining attention from value investors and FinTok for its transition from a healthcare royalty company to a mini biotech holding firm. Despite a low-key profile, its strategy of accumulating cash, executing share buybacks, and making strategic biotech investments offers potential for significant growth. The company's stable royalty income coupled with active investments in oncology, infectious disease, and rare disease assets provides a unique risk-reward profile for those seeking a less volatile healthcare play.
Innoviva (NASDAQ:INVA) Shares Cross Above Two Hundred Day Moving Average - Here's What Happened
Innoviva (NASDAQ:INVA) shares recently crossed above their 200-day moving average, trading at $19.76. Analysts have a "Moderate Buy" rating with an average target price of $38.80, and the company reported strong quarterly earnings, beating expectations for EPS and revenue. Institutional investors hold approximately 99.12% of the stock.
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
This article highlights two biotech companies, Axsome Therapeutics Inc. (AXSM) and Innoviva Inc. (INVA), as top stocks to watch in early 2026 due to significant regulatory updates and strong product pipelines. Axsome has received positive FDA news for its neurological disorder treatments, while Innoviva's newly approved gonorrhea treatment, Nuzolvence, and other strong product sales are expected to drive growth. Both companies are viewed optimistically by Wall Street analysts.
Innoviva, Inc. (INVA) Stock Report: Exploring A 62% Upside Potential
Innoviva, Inc. (INVA) is a biotechnology company with a market cap of $1.5 billion, showing a potential upside of 62.26%. The company demonstrates robust revenue growth of 20.40% and efficient use of shareholder equity with a 15.17% ROE, alongside a strong free cash flow. Analyst ratings are predominantly positive with an average target price of $32.50, although short-term technical indicators suggest potential overbought conditions.
Synergy Asset Management LLC Invests $1.85 Million in Innoviva, Inc. $INVA
Synergy Asset Management LLC has acquired a new position in Innoviva, Inc. (NASDAQ:INVA), purchasing 101,459 shares valued at approximately $1.85 million. Innoviva recently reported strong quarterly earnings, exceeding consensus estimates for both EPS and revenue. Analyst sentiment for the biotechnology company is generally positive, with a "Moderate Buy" consensus rating.
Avoiding Lag: Real-Time Signals in (INVA) Movement
This article analyzes Innoviva Inc. (NASDAQ: INVA) using predictive AI, highlighting a neutral near-term sentiment that could moderate mid-term weakness. It identifies a strong risk-reward short setup and outlines three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis. The piece emphasizes real-time signals and institutional-grade analysis for optimizing trading decisions.
Innoviva’s Stock Under the Microscope: Is INVA Quietly Setting Up Its Next Move?
Innoviva's stock has shown measured movement recently, indicating cautious market sentiment despite its steady royalty income and strategic expansion into infectious disease and critical care. The company's performance over the past year has resulted in a moderate single-digit percentage gain for investors, reflecting a stable yet unspectacular growth profile. Analysts lean mildly positive, with price targets suggesting limited but positive upside, positioning INVA as a "selective opportunity" for patient investors.
Innoviva’s Stock Under the Microscope: Is INVA Quietly Setting Up Its Next Move?
Innoviva's stock has shown recent stability within a narrow range, indicating market caution rather than capitulation. The company's strategy focuses on protecting royalty income while expanding into new therapeutic areas, leading analysts to a cautiously optimistic "Hold" to "Buy" stance. Future valuation will depend on updated royalty trajectories, business development, and the broader economic environment for healthcare investments.
Innoviva (INVA): Valuation Check After FDA Approval of First-in-Class NUZOLVENCE Antibiotic
Innoviva (INVA) has received FDA approval for NUZOLVENCE, a single-dose oral antibiotic for uncomplicated gonorrhea, which could significantly impact its growth. Despite a 13.62% year-to-date increase and a 51.73% three-year total shareholder return, the stock appears undervalued, trading at a 36% discount to intrinsic value and 35% below consensus targets. The company's price-to-earnings ratio of 11.6x is significantly lower than the pharmaceuticals industry average of 19.7x, suggesting potential for upward movement if Innoviva continues to perform.
December 2026 Options Now Available For Innoviva (INVA)
New options contracts for Innoviva Inc (INVA) with a December 2026 expiration began trading today. These long-dated contracts offer an opportunity for sellers of puts or calls to achieve higher premiums due to the extended time value, presenting a potential return for covered call strategies.
How Investors May Respond To Innoviva (INVA) Winning FDA Approval For First-In-Class Gonorrhea Drug
Innoviva, Inc. (INVA) recently gained FDA approval for NUZOLVENCE, a single-dose oral antibiotic for uncomplicated gonorrhea, marking a significant development in treating antibiotic-resistant infections. This approval aligns with Innoviva's strategic shift towards a more diversified infectious disease business. The market's response will hinge on the commercialization success and adoption of this new treatment, as Innoviva navigates both the opportunities and risks associated with its concentrated product portfolio.
How Investors May Respond To Innoviva (INVA) Winning FDA Approval For First-In-Class Gonorrhea Drug
Innoviva (INVA) recently received FDA approval for NUZOLVENCE, a first-in-class, single-dose oral antibiotic for uncomplicated gonorrhea, marking a significant advancement in addressing antibiotic resistance. This approval strengthens Innoviva's antibiotic franchise and aligns with its strategic shift towards a more diversified infectious disease and critical care business. Investors will now focus on the company's commercialization execution and ability to translate this therapy into market uptake and revenue.
H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating
H.C. Wainwright has updated its price target for Innoviva (INVA) to $46 from $45, maintaining a Buy rating on the stock. This adjustment follows the FDA approval of NUZOLVENCE® (zoliflodacin), a new oral antibiotic for gonorrhea, on December 12. The approval is based on a successful Phase 3 clinical trial and marks a significant achievement for Innoviva.
H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating
H.C. Wainwright increased its price target for Innoviva (INVA) to $46 from $45, while maintaining a Buy rating. This adjustment follows the FDA approval of NUZOLVENCE (zoliflodacin), a new oral antibiotic for uncomplicated gonorrhea, on December 12. The approval marks a significant milestone as it's one of the first new FDA-approved treatments for the condition in nearly two decades.
Technical Reactions to INVA Trends in Macro Strategies
This article provides a technical analysis of Innoviva Inc. (NASDAQ: INVA), highlighting weak near and mid-term sentiment and a neutral long-term outlook. It presents institutional trading strategies, including long, breakout, and short positions, and details AI-generated signals for different time horizons. The analysis identifies a strong risk-reward short setup for INVA.
12 Small Cap Stocks to Buy with Huge Upside Potential
This article highlights Innoviva, Inc. (NASDAQ: INVA) as a promising small-cap stock with significant upside potential. The company recently received FDA approval for NUZOLVENCE®, a new antibiotic for gonorrhea, leading to a raised price target from H.C. Wainwright. Innoviva, Inc. focuses on developing and commercializing biopharmaceuticals.
INVA: HC Wainwright & Co. Maintains Buy Rating and Raises Price Target | INVA Stock News
HC Wainwright & Co. has reiterated its Buy rating for Innoviva (INVA) and increased its price target from $45.00 to $46.00, reflecting continued confidence in the company's performance. This adjustment follows several other recent analyst activities, including Cantor Fitzgerald maintaining an Overweight rating and Goldman Sachs initiating coverage with a Sell rating. Innoviva, which manages a portfolio of royalty healthcare assets, currently has an average brokerage recommendation of "Outperform" from 4 firms, with an average target price suggesting a 60.05% upside from its current price.
Innoviva (INVA): Revisiting Valuation After a Strong Multi‑Year Share Price Run
Innoviva (INVA) has experienced a strong multi-year share price run, generating substantial cash from its royalty-driven respiratory portfolio. Despite a robust 18.56% year-to-date gain and a 61.55% 3-year total shareholder return, the stock appears undervalued with a P/E ratio of 12.1x, significantly lower than the industry average and its estimated fair P/E of 17x. A Discounted Cash Flow (DCF) model suggests an even greater undervaluation, with the stock trading at a 62% discount to its fair value of $54.61 per share.
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
The U.S. FDA has approved NUZOLVENCE® (zoliflodacin), a first-in-class, single-dose oral antibiotic, for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. This approval marks a significant advancement as it's one of the first new treatments for gonorrhea in nearly two decades, addressing the growing concern of antibiotic resistance. NUZOLVENCE demonstrated non-inferiority to standard treatments in a large Phase 3 trial and is expected to be commercialized in the second half of 2026.
Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Rating of "Moderate Buy" from Analysts
Innoviva, Inc. (NASDAQ:INVA) has received a "Moderate Buy" consensus rating from seven analysts, with an average 1-year price target of $38.60. The company reported strong quarterly earnings, significantly beating revenue and EPS estimates. Innoviva's stock currently trades in the low-$20s with a market capitalization of approximately $1.54 billion and high institutional ownership.
US FDA approves Innoviva’s oral antibiotic for gonorrhea
The U.S. FDA has approved Innoviva's oral antibiotic, Nuzolvence, for treating gonorrhea, offering a new alternative to injectable treatments. The drug, which targets multidrug-resistant strains, will be available in the U.S. next year and aims to address the growing public health crisis of antibiotic-resistant gonorrhea. This approval introduces a much-needed oral option alongside the currently recommended injectable ceftriaxone.
US FDA approves Innoviva's oral antibiotic for gonorrhea
The U.S. FDA has approved Innoviva's oral antibiotic, Nuzolvence, for treating gonorrhea, providing an alternative to the previously sole injectable treatment. This approval addresses the growing issue of antibiotic resistance in gonorrhea, which affects millions globally. Nuzolvence is planned for release in the second half of 2026, with pricing expected to be more affordable outside the U.S.
Innoviva (NASDAQ: INVA) gets FDA approval for single-dose oral antibiotic NUZOLVENCE for gonorrhea
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced FDA approval for NUZOLVENCE® (zoliflodacin), a first-in-class, single-dose oral antibiotic for uncomplicated urogenital gonorrhea. This marks the first new treatment against Neisseria gonorrhoeae infection approved by the FDA in nearly two decades, offering a crucial weapon against rising global antibiotic resistance. The company plans to commercialize NUZOLVENCE in the second half of 2026.
US FDA approves Innoviva’s oral antibiotic for gonorrhea
The U.S. FDA has approved Innoviva's oral antibiotic, Nuzolvence, for treating uncomplicated gonorrhea in patients aged 12 and older, offering an alternative to current injectable treatments. The drug, developed in partnership with Global Antibiotic Research & Development Partnership, targets multidrug-resistant strains of gonorrhea and will be available next year. Its approval addresses the growing public health concern of antibiotic resistance in gonorrhea.
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
Innoviva Specialty Therapeutics has announced the publication of positive Phase 3 data for its investigational oral antibiotic, zoliflodacin, in The Lancet. The study demonstrated zoliflodacin's non-inferiority to existing combination therapy for uncomplicated urogenital gonorrhea, addressing a critical need for new treatments against drug-resistant strains. This marks a significant step towards a single-dose oral option for a widespread public health threat.
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
Innoviva Specialty Therapeutics announced the publication of positive Phase 3 trial results for its investigational antibiotic, zoliflodacin, in The Lancet. The study showed zoliflodacin to be non-inferior to ceftriaxone and azithromycin for treating uncomplicated urogenital gonorrhea, addressing a significant public health threat of drug-resistant infections. The U.S. FDA has granted zoliflodacin QIDP designation, and its New Drug Application has a target action date of December 15, 2025.
Nuzolvence, Blujepa win FDA nods for gonorrhea
The FDA has approved two new therapies, Nuzolvence (zoliflodacin) by Innoviva Inc. and Blujepa (gepotidacin) by GSK plc, for the treatment of gonorrhea. Both products received fast track, qualified infectious disease product, and priority review designations, offering additional antibiotic options comparable to current standards of care.
